


SUBSTITUTE FORM PTO-1449
U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

6056-268

SERIAL NO.

10/018,581



INFORMATION DISCLOSURE CITATION

APPLICANT:

E. Premkumar Reddy, et. al.

FILING DATE

March 18, 2002

GROUP

1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
mm2		AT402936B	1997-09-25	Austria			Derwent Abstr	
mm2		AT402732B	1997-08-25	Austria			Derwent Abstr	
mm2		WO9414977	1994-07-07	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER		DATE CONSIDERED	
mm2		TECH CENTER 1600/2900 6/5/03	
<p>EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE <div style="text-align: center; font-weight: bold; font-size: 1.2em;"> INFORMATION DISCLOSURE CITATION </div>	ATTY. DOCKET NO. 6056-268	SERIAL NO. Unassigned #2
APPLICANT: E. Premkumar Reddy et al.		
FILING DATE Herewith		GROUP Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	AA					
	AB					
	AC					
	AD					
	AE					

FOREIGN PATENT DOCUMENTS

DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
AF					
AG					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

mmr	✓AH	LAUFER et al., Development of an in-vitro test system for the evaluation of cyclooxygenase-2 inhibitors, Inflamm. Res. 01 March 1999, Vol. 48, pages 133-138, see entire document.
	✓AI	BRIDEAU, et al., A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors, Inflamm. Res. 01 February 1996, Vol. 45, pages 68-74, see entire document, especially page 68, col. 2; page 69, col. 2.
	AJ	MCCORMACK, K., Roles of COX-1 and COX-2, J. Rheumatol., 01 November 1998, Vol. 25, pages 2279-2280, see entire document.
	✓AK	XU, N. et al., A mutant α subunit of G_{12} potentiates the eicosanoid pathway and is highly oncogenic in NIH 3T3 cells., Proc. Natl. Acad. Sci USA, 01 July 1993, Vol. 90, pages 6741-6745, see entire document.
	✓AL	DERMOTT et al., Oncogenic mutant of $G_{\alpha_{12}}$ stimulates cell proliferation through cyclooxygenase-2 signaling pathway, <i>Oncogene</i> (1999) 18, 7185-7189.
	✓AM	PRASAD et al., Activated mutant of $G_{\alpha_{13}}$ induces EGR-1, c-fos, and transformation in NIH 3T3 cells, <i>Oncogene</i> (1994), 9, 2425-2429.
	✓AN	ZONES et al., $G_{\alpha_{12}}$ requires acylation for its transforming activity, <i>Biochem.</i> 1998, 37, 3196-3202.
	✓AO	STRATHMANN et al., $G_{\alpha_{12}}$ and $G_{\alpha_{13}}$ subunits define a fourth class of G protein α subunits, Proc. Natl. Acad. Sci. USA, Vol. 88, pp. 5582-5586, July 1991.
	✓AP	KUJUBU et al., TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue, The Journal of Biol. Chem., Vol. 266, No. 20, July 15, 1991, pp. 12866-12872.
	✓AQ	SLICE et al., $G_{\alpha_{13}}$ stimulates rho-dependent activation of the cyclooxygenase-2 promoter, The Journal of Biol. Chem., Vol. 274, No. 39, September 24, 1999, pp. 27562-27566.
	✓AR.	DHANASEKARAN et al., Protein kinase C-dependent and -independent activation of Na ⁺ /H ⁺ exchanger by $G_{\alpha_{12}}$ class of G proteins, The Journal of Biol. Chem., Vol. 269, No. 16, April 22, 1994, pp. 11802-11806.
mmr	✓AS	PRASAD et al., Activation of Jun Kinase/Stress-activated protein kinase by GTPase-deficient mutants of $G_{\alpha_{12}}$ and $G_{\alpha_{13}}$, The Journal of Biol. Chem., Vol. 270, No. 31, August 4, 1995, pp. 18655-18659.

EXAMINER mmr	DATE CONSIDERED 6/5/03
---	---

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.